MedTrace Logo

fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia

NCT01046526 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2017-07-02

No results posted yet for this study

Summary

Background:

* Individuals who have schizophrenia are significantly more likely to smoke than the general population, which leads to increased smoking-related illnesses and high rates of nicotine dependence. Research suggests that high rates of smoking and nicotine addiction in people with schizophrenia are related to the fact that nicotine temporally improves performance in several cognitive tasks, including sensory gating, long-term memory, and visual tracking-all of which are affected by schizophrenia.
* Smoking among schizophrenia patients may be a form of self-medication, since nicotine may temporarily treat and improve cognitive deficits caused by schizophrenia. Researchers are interested in studying the effects of nicotine on the brain activity of individuals with schizophrenia to better understand how nicotine affects the brain regions connected to memory, visual tracking, and attention.

Objectives:

* To identify specific brain regions involved in the anticipatory learning deficits found in schizophrenia patients who smoke.
* To determine whether and how nicotine enhances performance in these regions.

Eligibility:

\- Smokers (at least 10 cigarettes per day) between 18 and 50 years of age who either are healthy volunteers or have been diagnosed with schizophrenia/schizoaffective disorder.

Design:

* Participants will be asked to avoid consuming alcohol and restrict consuming caffeinated beverages for 24 hours before the study days. Participants will provide urine and breath samples at the start of the study to be tested for chemicals that may interfere with the study.
* The study will require two to four visits, with two fMRI sessions and other visits for a clinical interview or training.

Participants will have a training session with a possible mock MRI scan to learn how to do tasks that track eye movement and measure ability to pay attention.

* During the fMRI scanning sessions, participants will receive either a nicotine patch or a placebo patch without nicotine. After the patch is in place, participants will perform tasks while receiving MRI scans. The scans will take up to 2 hours.
* Participants will provide blood samples after finishing the MRI sessions.

Conditions

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • George R Uhl, M.D. · National Institute on Drug Abuse (NIDA)

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-08
Completion
2012-05-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01046526 on ClinicalTrials.gov